ENSG00000130396 |
|
breast ductal adenocarcinoma |
frameshift_variant |
10.79% (63/584) |
2 entries |
ENSG00000130396 |
|
colorectal adenocarcinoma |
frameshift_variant |
8.436% (96/1138) |
2 entries |
ENSG00000130396 |
|
melanoma |
missense_variant |
11.88% (12/101) |
2 entries |
ENSG00000130396 |
|
colorectal adenocarcinoma |
stop_gained |
8.436% (96/1138) |
2 entries |
ENSG00000130396 |
|
colorectal adenocarcinoma |
missense_variant |
8.436% (96/1138) |
4 entries |
ENSG00000130396 |
|
hemangioblastoma |
sequence_alteration |
40.62% (13/32) |
1 entry |
ENSG00000130396 |
|
colorectal adenocarcinoma |
sequence_alteration |
8.436% (96/1138) |
1 entry |
ENSG00000130396 |
|
breast ductal adenocarcinoma |
stop_gained |
10.79% (63/584) |
2 entries |
ENSG00000130396 |
|
melanoma |
conservative_inframe_deletion |
11.88% (12/101) |
1 entry |
ENSG00000130396 |
|
colon adenocarcinoma |
missense_variant |
5.263% (38/722) |
4 entries |
ENSG00000130396 |
|
esophageal adenocarcinoma |
sequence_alteration |
5.251% (23/438) |
1 entry |
ENSG00000130396 |
|
esophageal adenocarcinoma |
missense_variant |
5.251% (23/438) |
2 entries |
ENSG00000130396 |
|
breast carcinoma |
sequence_alteration |
1.488% (21/1411) |
1 entry |
ENSG00000130396 |
|
clear cell renal carcinoma |
missense_variant |
1.379% (19/1378) |
3 entries |
ENSG00000130396 |
|
lung adenocarcinoma |
missense_variant |
2.049% (25/1220) |
4 entries |
ENSG00000130396 |
|
female breast carcinoma |
missense_variant |
1.023% (4/391) |
2 entries |
ENSG00000130396 |
|
hepatocellular carcinoma |
missense_variant |
1.222% (11/900) |
1 entry |
ENSG00000130396 |
|
prostate adenocarcinoma |
missense_variant |
4.127% (60/1454) |
1 entry |
ENSG00000130396 |
|
chronic lymphocytic leukemia |
sequence_alteration |
1.014% (9/888) |
1 entry |
ENSG00000130396 |
|
clear cell renal carcinoma |
sequence_alteration |
1.379% (19/1378) |
1 entry |
ENSG00000130396 |
|
prostate adenocarcinoma |
stop_gained |
4.127% (60/1454) |
1 entry |
ENSG00000130396 |
|
pancreatic neuroendocrine tumor |
stop_gained |
8.125% (13/160) |
1 entry |
ENSG00000130396 |
|
colon adenocarcinoma |
frameshift_variant |
5.263% (38/722) |
2 entries |
ENSG00000130396 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
8.228% (13/158) |
1 entry |
ENSG00000130396 |
|
gastric intestinal type adenocarcinoma |
stop_gained |
3.529% (3/85) |
1 entry |
ENSG00000130396 |
|
cecum adenocarcinoma |
missense_variant |
8.8% (11/125) |
2 entries |
ENSG00000130396 |
|
rectal adenocarcinoma |
missense_variant |
2.262% (5/221) |
2 entries |
ENSG00000130396 |
|
brain glioblastoma |
sequence_alteration |
0.54% (5/926) |
1 entry |
ENSG00000130396 |
|
melanoma |
sequence_alteration |
11.88% (12/101) |
1 entry |
ENSG00000130396 |
|
colon adenocarcinoma |
stop_gained |
5.263% (38/722) |
4 entries |
ENSG00000130396 |
|
squamous cell lung carcinoma |
missense_variant |
1.818% (15/825) |
1 entry |
ENSG00000130396 |
|
prostate carcinoma |
sequence_alteration |
2.893% (14/484) |
2 entries |
ENSG00000130396 |
|
basal cell carcinoma |
missense_variant |
10.34% (6/58) |
1 entry |
ENSG00000130396 |
|
T-cell acute lymphoblastic leukemia |
gene_fusion |
2.332% (9/386) |
3 entries |
ENSG00000130396 |
|
bladder transitional cell carcinoma |
missense_variant |
1.46% (2/137) |
2 entries |
ENSG00000130396 |
|
prostate carcinoma |
missense_variant |
2.893% (14/484) |
4 entries |
ENSG00000130396 |
|
colon adenocarcinoma |
sequence_alteration |
5.263% (38/722) |
4 entries |
ENSG00000130396 |
|
small cell lung carcinoma |
missense_variant |
1.846% (6/325) |
2 entries |
ENSG00000130396 |
|
clear cell renal carcinoma |
stop_gained |
1.379% (19/1378) |
1 entry |
ENSG00000130396 |
|
gastric adenocarcinoma |
sequence_alteration |
3.405% (19/558) |
1 entry |
ENSG00000130396 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
3.177% (40/1259) |
1 entry |
ENSG00000130396 |
|
prostate adenocarcinoma |
sequence_alteration |
4.127% (60/1454) |
1 entry |
ENSG00000130396 |
|
acute myeloid leukemia |
gene_fusion |
3.66% (34/929) |
7 entries |
ENSG00000130396 |
|
skin melanoma |
missense_variant |
2.482% (24/967) |
4 entries |
ENSG00000130396 |
|
skin melanoma |
stop_gained |
2.482% (24/967) |
1 entry |
ENSG00000130396 |
|
colon adenocarcinoma |
conservative_inframe_deletion |
5.263% (38/722) |
2 entries |
ENSG00000130396 |
|
esophageal squamous cell carcinoma |
missense_variant |
1.331% (9/676) |
6 entries |
ENSG00000130396 |
|
brain glioblastoma |
missense_variant |
0.54% (5/926) |
2 entries |
ENSG00000130396 |
|
cecum adenocarcinoma |
sequence_alteration |
8.8% (11/125) |
1 entry |
ENSG00000130396 |
|
ependymoma |
sequence_alteration |
2.174% (1/46) |
1 entry |
ENSG00000130396 |
|
ovarian serous adenocarcinoma |
stop_gained |
0.4458% (3/673) |
1 entry |
ENSG00000130396 |
|
non-small cell lung carcinoma |
conservative_inframe_deletion |
1.613% (1/62) |
1 entry |
ENSG00000130396 |
|
ovarian serous adenocarcinoma |
missense_variant |
0.4458% (3/673) |
1 entry |
ENSG00000130396 |
|
angiosarcoma |
conservative_inframe_deletion |
7.692% (1/13) |
1 entry |
ENSG00000130396 |
|
female breast carcinoma |
frameshift_variant |
1.023% (4/391) |
1 entry |
ENSG00000130396 |
|
medulloblastoma |
sequence_alteration |
4.167% (1/24) |
1 entry |
ENSG00000130396 |
|
T-cell acute lymphoblastic leukemia |
missense_variant |
2.332% (9/386) |
1 entry |
ENSG00000130396 |
|
adenosquamous lung carcinoma |
stop_gained |
9.091% (1/11) |
1 entry |
ENSG00000130396 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
1.331% (9/676) |
1 entry |
ENSG00000130396 |
|
cecum adenocarcinoma |
conservative_inframe_deletion |
8.8% (11/125) |
1 entry |
ENSG00000130396 |
|
diffuse gastric adenocarcinoma |
missense_variant |
1.266% (1/79) |
1 entry |
ENSG00000130396 |
|
hepatocellular carcinoma |
stop_gained |
1.222% (11/900) |
1 entry |
ENSG00000130396 |
|
pharyngeal squamous cell carcinoma |
missense_variant |
3.226% (1/31) |
1 entry |
ENSG00000130396 |
|
Chronic Eosinophilic Leukemia, Not Otherwise Specified |
gene_fusion |
50.0% (1/2) |
1 entry |
ENSG00000130396 |
|
angiosarcoma |
sequence_alteration |
7.692% (1/13) |
1 entry |
ENSG00000130396 |
|
basal cell carcinoma |
stop_gained |
10.34% (6/58) |
1 entry |
ENSG00000130396 |
|
mucosal melanoma |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000130396 |
|
Thymoma Type B3 |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000130396 |
|
lung adenocarcinoma |
sequence_alteration |
2.049% (25/1220) |
1 entry |
ENSG00000130396 |
|
metaplastic breast carcinoma |
missense_variant |
1.961% (1/51) |
1 entry |
ENSG00000130396 |
|
bile duct adenocarcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000130396 |
|
non-small cell lung carcinoma |
sequence_alteration |
1.613% (1/62) |
1 entry |
ENSG00000130396 |
|
metaplastic breast carcinoma |
sequence_alteration |
1.961% (1/51) |
1 entry |
ENSG00000130396 |
|
T-cell acute lymphoblastic leukemia |
sequence_alteration |
2.332% (9/386) |
1 entry |
ENSG00000130396 |
|
osteosarcoma |
missense_variant |
1.724% (2/116) |
1 entry |
ENSG00000130396 |
|
B-cell acute lymphoblastic leukemia |
gene_fusion |
1.818% (1/55) |
1 entry |
ENSG00000130396 |
|
diffuse large B-cell lymphoma |
missense_variant |
0.3279% (1/305) |
1 entry |
ENSG00000130396 |
|
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
0.5988% (1/167) |
1 entry |
ENSG00000130396 |
|
cecum adenocarcinoma |
stop_gained |
8.8% (11/125) |
1 entry |
ENSG00000130396 |
|
nasopharyngeal squamous cell carcinoma |
conservative_inframe_deletion |
0.5988% (1/167) |
1 entry |
ENSG00000130396 |
|
lung adenocarcinoma |
frameshift_variant |
2.049% (25/1220) |
1 entry |
ENSG00000130396 |
|
basal cell carcinoma |
sequence_alteration |
10.34% (6/58) |
1 entry |
ENSG00000130396 |
|
Thyroid Gland Oncocytic Follicular Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000130396 |
|
salivary gland adenoid cystic carcinoma |
frameshift_variant |
1.587% (1/63) |
1 entry |
ENSG00000130396 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000130396 |
|
osteosarcoma |
sequence_alteration |
1.724% (2/116) |
1 entry |
ENSG00000130396 |
|
female breast carcinoma |
sequence_alteration |
1.023% (4/391) |
1 entry |
ENSG00000130396 |
|
ACTH-Producing Pituitary Gland Adenoma |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000130396 |
|
small cell lung carcinoma |
sequence_alteration |
1.846% (6/325) |
1 entry |
ENSG00000130396 |
|
Cervical Small Cell Carcinoma |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000130396 |
|
primary peritoneal carcinoma (disease) |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000130396 |
|
acute myeloid leukemia |
frameshift_variant |
3.66% (34/929) |
1 entry |
ENSG00000130396 |
|
skin melanoma |
sequence_alteration |
2.482% (24/967) |
1 entry |
ENSG00000130396 |
|
Cervical Small Cell Carcinoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000130396 |
|
lung adenocarcinoma |
stop_gained |
2.049% (25/1220) |
1 entry |
ENSG00000130396 |
|
T-cell acute lymphoblastic leukemia |
stop_gained |
2.332% (9/386) |
1 entry |
ENSG00000130396 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
3.529% (3/85) |
1 entry |